| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | A portion of amino acids 115-233 from the human protein was used as the immunogen for this TPSAB1 antibody. |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
TPSAB1 Antibody / Mast Cell Tryptase is a research-use primary antibody intended for detection of TPSAB1 in experimental workflows. It is supplied in Purified format. Key antibody attributes include Mouse, Monoclonal (mouse origin), clone TPSAB1/1961, isotype Mouse IgG1, kappa. Applications listed for this product include IHC-P. Reported/annotated localization context: Cytoplasmic, secreted. Species reactivity (as provided): Human.
Key elements and design rationale
- Target: TPSAB1 (Mast Cell Tryptase) — selectivity and interpretation should be considered in the context of isoforms, post-translational modifications, and related family members when applicable.
- Format: Purified — format can influence background, multiplexing compatibility, and downstream detection strategies.
- Antibody identity: Mouse, Monoclonal (mouse origin), clone TPSAB1/1961, isotype Mouse IgG1, kappa — these attributes help align secondary reagents and controls (e.g., isotype-matched controls) with your assay design.
- Localization: Cytoplasmic, secreted — expected subcellular distribution can guide band/structure interpretation and help flag off-target signal.
- Product notes (from provided description): Tryptases comprise a family of trypsin-like serine proteases (peptidase family S1). Tryptases are stored in mast cell secretory granules and basophils. Mast cells are connective tissue cells derived from blood-forming tissues that line arterial walls and secrete substances, which mediate inflammatory and immune responses. Tryptases are released into the extracellular environment and are resistant to all known endogenous proteinase inhibitors. This antibody reacts with mast cells distributed in skin, synovium, lung, and heart. This antibody does not bind with any other cell type. Human mast cell tryptase is considered to be an important marker of mast cell activation and is an important mediator of inflammation. Mastocytosis is a term collectively used for a group of disorders in which there is abnormal accumulation of mast cells in one or multiple organs. Anti-tryptase, combined with anti-CD2, anti-CD25, and anti-CD117, can be useful in identifying reactive mast cell hyperplasia, myelogenous neoplasms, mast cell leukemia, and mastocytosis.
Where multiple assay formats are possible, align the antibody format, host/isotype, and listed applications with your detection system and controls to support clear interpretation of signal.
Biological background
In this catalog, TPSAB1 is positioned within Immunology & Inflammation, Leukemia research contexts. Localization annotations (e.g., Cytoplasmic, secreted) can help contextualize expected signal patterns in imaging and fractionation-based readouts. For authoritative gene/protein nomenclature, domains/isoforms, and curated functional annotations, consult resources such as UniProt, NCBI Gene, and Ensembl.
Research relevance and current trends
- Higher-plex and spatially resolved readouts (e.g., multiplex IF/IHC, spatial omics) are increasing demand for well-characterized primary antibodies with clearly stated host/isotype and labeling strategies.
- Genetic perturbation controls (knockout/knockdown) and orthogonal measurements (e.g., RNA vs protein) are commonly used to strengthen target attribution when interpreting antibody-derived signals.
- Reproducibility initiatives emphasize transparent reporting of antibody identity (clone, host, isotype) and experimental context to improve cross-study comparability.
Common research applications
- IHC-P: interpret changes in signal in the context of sample composition, epitope accessibility, and potential isoform/PTM differences across conditions.
- Typical workflow themes: IHC on FFPE tissue, ELISA binding assay, Specificity controls.
- Workflow notes: Detect TPSAB1 by IHC in FFPE tissue sections (optimize antigen retrieval + dilution), Measure binding to TPSAB1 peptide/protein by ELISA with dilution series (include blanks), Confirm specificity using KO/KD or peptid…
When comparing conditions, consistent sample processing and appropriate negative/positive controls support interpretation of qualitative localization differences and quantitative abundance changes.
Notes for experimental interpretation
- Isoforms and post-translational modifications may shift apparent molecular weight or epitope accessibility, especially across cell states or treatments.
- Species and tissue context can affect sequence conservation, expression level, and background binding; predicted reactivity should be verified in your sample.
- Control concepts include isotype-matched controls, secondary-only controls (for indirect detection), and genetic/orthogonal controls (e.g., KO/KD, independent antibodies, or RNA measurements) when feasible.
Monoclonal and polyclonal antibodies can differ in epitope recognition breadth and lot-to-lot characteristics; consider clonality and clone information (when provided) alongside your assay requirements. Conjugated formats may simplify detection but can change background and multiplexing behavior compared with unconjugated primaries.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
